Fractyl Logo


Press Releases

Nov 19, 2015

Fractyl Announces Completion of $57 Million Series C Investment

Deerfield Capital Joins Existing Investor Group

Read More

Sep 18, 2015

Fractyl Announces Positive Results from 39-Patient Study of Revita DMR System

Significant changes in blood sugar control in patients with uncontrolled type 2 diabetes

Read More

Jan 16, 2015

First Patients Enrolled in Multicenter Clinical Trial of Fractyl Revita DMR System

Trial will evaluate implant-free duodenal mucosal resurfacing for type 2 diabetes

Read More

Jan 12, 2015

Fractyl Labs Announces Approval to Initiate Multicenter Clinical Trial of Revita DMR Procedure

Emergent Medical Partners Joins Existing Fractyl Investor Syndicate

Read More

Sep 4, 2014

Fractyl Labs Announces Positive Clinical Data for First Procedural Therapy to Treat Type 2 Diabetes

Mithril Capital Management Leads $40M Series C Financing to Join Early Investors General Catalyst, Bessemer and Domain Associates Trial Shows Revita™ Duodenal Mucosal Resurfacing™ (DMR) Procedure Dramatically Improves Glucose Control in Patients with Type 2 Diabetes

Read More

In the News